Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the ...

The chatter around ALLO is a tug-of-war between AI-driven optimism and concentration concerns. Here’s what’s trending: Analysts are spotting bullish technical patterns, eyeing a breakout above $0.245.

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Allogene's new CEO Zachary Roberts outlined a strategic refocus on leveraging the intrinsic advantages of allogeneic (off-the-shelf) CAR-T — ready availability, consistent product quality, and ability ...

According to long-term price projections, the estimated Allora price for 2040 is $3.75. The predicted value is based on current trends and technical indicators. Market conditions for such an extended ...

Big Bullish move in ALLO Hello Traders! Allousdt has broken final support and next support is way too much low. So its now planning to use final support to form a reversal pattern and it is heading ...

ALLO/USDT (4h) Testing a Falling Wedge Breakout ALLO/USDT has been trading inside a large falling wedge on the 4H chart, with price forming lower highs beneath descending resistance while the lower ...

Profound Medical Corp. is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the ablation of diseased tissue ...